Mass Tort brief
Daubert Gatekeeping and Federal Bellwethers
Judges test scientific causation and trial deadlines across GLP-1 stomach paralysis, infant formula, and toxic exposure dockets.
Mass Tort
The Ozempic litigation comes down to Daubert gatekeeping — if the judge excludes the plaintiffs' science, thousands of stomach paralysis claims collapse.
BackgroundFederal Rule of Evidence 702 requires judges to act as evidentiary gatekeepers, screening expert scientific methodology before claims reach a jury. Drugmakers Novo Nordisk and Eli Lilly contend that plaintiffs lack reliable epidemiological proof that GLP-1 therapies directly trigger chronic gastroparesis.
- Arguments scheduled for October 13 evaluate whether plaintiff experts can testify on gastroparesis, bowel obstruction, and ileus mechanisms across thousands of pending claims.
- The primary gastrointestinal docket reached 4,025 pending lawsuits, alongside 247 actions in a companion proceeding alleging non-arteritic anterior ischemic optic neuropathy vision loss.
- A defense victory on general causation would dismantle the litigation, whereas allowing the testimony forces manufacturers toward multibillion-dollar settlement negotiations.
Mass Tort
Federal judges gave the government until October 30 to settle Camp Lejeune claims — using incoming trials to force an end to four years of administrative delays.
BackgroundCongress passed the Camp Lejeune Justice Act in 2022 to allow veterans and civilian base residents exposed to toxic military water to sue for historic illnesses. Administrative settlement offers managed by the Navy resolved fewer than 1% of the 400,000 claims filed, pushing hundreds of thousands into federal courts.
- Judge Terrence W. Boyle scheduled the first two Track 1 bench trials involving kidney cancer for October 26 and November 9, creating imminent trial pressure.
- Judges mandated the October 30 framework to avert decades of individualized trials, threatening severe procedural sanctions if negotiations fail to produce concrete compensation tiers.
- Government counsel faces mounting criticism from bipartisan lawmakers as administrative processing delays leave hundreds of thousands of aging veterans without financial resolution.
Mass Tort
Abbott faces its first federal jury test on infant formula warnings — determining whether its earlier $670M settlement sets the benchmark for the remaining docket.
BackgroundChicago multidistrict litigation consolidates claims alleging formula makers failed to warn neonatal units that cow's-milk fortifiers heighten necrotizing enterocolitis risks. While Abbott previously resolved roughly 2,000 claims for $670 million, hundreds of active cases remain set for federal trial.
- The trial against Abbott follows an August defense verdict for Mead Johnson, creating contrasting bellwether precedents across the coordinated docket.
- Chief Judge Rebecca R. Pallmeyer presides over 844 active infant injury and wrongful death lawsuits in Chicago, shaping settlement pressure for remaining cases.
- Plaintiffs argue manufacturers concealed clinical studies showing donor human milk significantly reduces intestinal necrosis compared to bovine formulas, driving punitive damage requests.
Mass Tort
Depo-Provera claims topped 6,400 ahead of a November 30 deadline — funneling the majority of meningioma lawsuits into Pfizer's settlement program.
BackgroundDepo-Provera is an injectable progestin contraceptive utilized by millions of women worldwide for long-term birth control. European epidemiological findings published in recent years documented a sharp statistical association between prolonged medroxyprogesterone acetate use and intracranial meningiomas.
- Judge M. Casey Rodgers established a November 30 registration deadline for eligible claimants to enroll in a court-supervised master settlement program.
- The settlement program administered by BrownGreer is expected to resolve roughly 80% of pending federal personal-injury claims against Pfizer without individual trials.
- Plaintiffs contend that Pfizer marketed high-dose injections for decades without updating US warning labels to reflect known European epidemiological research.
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
